Patents by Inventor Adrian Tersteegen

Adrian Tersteegen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124522
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: April 12, 2023
    Publication date: April 18, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald Bierer, Ingo Flamme, Dmitry Zubov, Thomas Neubauer, Adrian Tersteegen, Cathleen Juhl, Marie Glatz, Jan Dreher, Simon Holton, Carsten Terjung, Lars Baumann, Thorsten Poethko, Jiancheng Xiong, Yibo Qiu
  • Patent number: 11912692
    Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 27, 2024
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
  • Patent number: 11884660
    Abstract: The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: January 30, 2024
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Mario Lobell, Hartmut Schirok, Adrian Tersteegen
  • Publication number: 20240010684
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory bicyclic compounds, as well as to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: October 29, 2021
    Publication date: January 11, 2024
    Inventors: Donald BIERER, Ingo FLAMME, Dmitry ZUBOV, Thomas NEUBAUER, Adrian TERSTEEGEN, Lars BAUMANN, Cathleen JUHL, Marie GLATZ, Jan DREHER, Simon HOLTON, Jiancheng XIONG, Jianchao XU
  • Publication number: 20230391761
    Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Application
    Filed: August 11, 2023
    Publication date: December 7, 2023
    Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
  • Patent number: 11773070
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: October 3, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Patent number: 11667675
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: June 6, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald Bierer, Ingo Flamme, Dmitry Zubov, Thomas Neubauer, Adrian Tersteegen, Cathleen Juhl, Marie Glatz, Jan Dreher, Simon Holton, Carsten Terjung, Lars Baumann, Thorsten Poethko, Jiancheng Xiong, Yibo Qiu
  • Publication number: 20230024752
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Application
    Filed: October 18, 2021
    Publication date: January 26, 2023
    Inventors: Eloisa JIMENEZ NUNEZ, Jens ACKERSTAFF, Susanne ROEHRIG, Alexander HILLISCH, Katharina MEIER, Stefan HEITMEIER, Adrian TERSTEEGEN, Jan STAMPFUSS, Pascal ELLERBROCK, Daniel MEIBOM, Dieter LANG
  • Publication number: 20230017200
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 19, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • Publication number: 20220396554
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2022
    Publication date: December 15, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • Patent number: 11427553
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 30, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Publication number: 20220144848
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Application
    Filed: December 18, 2019
    Publication date: May 12, 2022
    Inventors: Susanne ROEHRIG, Sebastian ESSIG, Pascal ELLERBROCK, Sonja ANLAUF, Thomas NEUBAUER, Alexander HILLISCH, Katharina MEIER, Stefan HEITMEIER, Adrian TERSTEEGEN, Martina SCHAFER, Jan STAMPFUSS, Dieter LANG, Eloisa JIMENEZ NUNEZ, Jens ACKERSTAFF, Henrik TELLER, Zengqiang ZOU, Ping LIU, Xianghai MENG, Frank LESSMANN
  • Patent number: 11180471
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: November 23, 2021
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Eloisa Jimenez Nunez, Jens Ackerstaff, Susanne Roehrig, Alexander Hillisch, Katharina Meier, Stefan Heitmeier, Adrian Tersteegen, Jan Stampfuss, Pascal Ellerbrock, Daniel Meibom, Dieter Lang
  • Publication number: 20210353630
    Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: November 18, 2021
    Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.
    Inventors: Stefan Nikolaus GRADL, Manuel ELLERMANN, Philip LIENAU, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU
  • Publication number: 20210246166
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: December 30, 2020
    Publication date: August 12, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald BIERER, Ingo FLAMME, Dmitry ZUBOV, Thomas NEUBAUER, Adrian TERSTEEGEN, Cathleen JUHL, Marie GLATZ, Jan DREHER, Simon HOLTON, Carsten TERJUNG, Lars BAUMANN, Thorsten POETHKO, Jiancheng XIONG, Yibo QIU
  • Publication number: 20210147414
    Abstract: The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.
    Type: Application
    Filed: April 3, 2019
    Publication date: May 20, 2021
    Inventors: Mario LOBELL, Hartmut SCHIROK, Adrian TERSTEEGEN
  • Publication number: 20200369633
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 2, 2018
    Publication date: November 26, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Publication number: 20200247783
    Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):
    Type: Application
    Filed: August 2, 2018
    Publication date: August 6, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Detlev Sülzle, Timothy Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson
  • Publication number: 20200061063
    Abstract: The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: April 2, 2019
    Publication date: February 27, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Chantal FÜRSTNER, Jens ACKERSTAFF, Alexander STRAUB, Heinrich MEIER, Hanna TINEL, Katja ZIMMERMANN, Adrian TERSTEEGEN, Dmitry ZUBOV, Raimund KAST, Jens SCHAMBERGER, Martina SCHÄFER, Kirsten BÖRNGEN
  • Publication number: 20190367478
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 5, 2019
    Inventors: Eloisa JIMENEZ NUNEZ, Jens ACKERSTAFF, Susanne RÖEHRIG, Alexander HILLISCH, Katharina MEIER, Stefan HEITMEIER, Adrian TERSTEEGEN, Jan STAMPFUSS, Pascal ELLERBROCK, Daniel MEIBOM, Dieter LANG